AtriCure Statistics
Total Valuation
AtriCure has a market cap or net worth of $1.33 billion. The enterprise value is $1.26 billion.
Important Dates
The last earnings date was Tuesday, May 5, 2026, after market close.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AtriCure has 50.64 million shares outstanding. The number of shares has increased by 1.81% in one year.
| Current Share Class | 50.64M |
| Shares Outstanding | 50.64M |
| Shares Change (YoY) | +1.81% |
| Shares Change (QoQ) | +0.35% |
| Owned by Insiders (%) | 4.05% |
| Owned by Institutions (%) | 98.03% |
| Float | 48.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 247.69 |
| PS Ratio | 2.41 |
| Forward PS | 2.10 |
| PB Ratio | 2.71 |
| P/TBV Ratio | 6.30 |
| P/FCF Ratio | 24.81 |
| P/OCF Ratio | 20.68 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 70.95, with an EV/FCF ratio of 23.48.
| EV / Earnings | n/a |
| EV / Sales | 2.28 |
| EV / EBITDA | 70.95 |
| EV / EBIT | n/a |
| EV / FCF | 23.48 |
Financial Position
The company has a current ratio of 4.29, with a Debt / Equity ratio of 0.15.
| Current Ratio | 4.29 |
| Quick Ratio | 2.97 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | 3.78 |
| Debt / FCF | 1.40 |
| Interest Coverage | -0.51 |
Financial Efficiency
Return on equity (ROE) is -0.97% and return on invested capital (ROIC) is -0.72%.
| Return on Equity (ROE) | -0.97% |
| Return on Assets (ROA) | -0.30% |
| Return on Invested Capital (ROIC) | -0.72% |
| Return on Capital Employed (ROCE) | -0.52% |
| Weighted Average Cost of Capital (WACC) | 11.02% |
| Revenue Per Employee | $409,005 |
| Profits Per Employee | -$3,402 |
| Employee Count | 1,350 |
| Asset Turnover | 0.89 |
| Inventory Turnover | 1.73 |
Taxes
In the past 12 months, AtriCure has paid $1.33 million in taxes.
| Income Tax | 1.33M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.30% in the last 52 weeks. The beta is 1.28, so AtriCure's price volatility has been higher than the market average.
| Beta (5Y) | 1.28 |
| 52-Week Price Change | -13.30% |
| 50-Day Moving Average | 29.08 |
| 200-Day Moving Average | 34.54 |
| Relative Strength Index (RSI) | 37.08 |
| Average Volume (20 Days) | 881,575 |
Short Selling Information
The latest short interest is 3.61 million, so 7.14% of the outstanding shares have been sold short.
| Short Interest | 3.61M |
| Short Previous Month | 3.54M |
| Short % of Shares Out | 7.14% |
| Short % of Float | 7.44% |
| Short Ratio (days to cover) | 5.98 |
Income Statement
In the last 12 months, AtriCure had revenue of $552.16 million and -$4.59 million in losses. Loss per share was -$0.10.
| Revenue | 552.16M |
| Gross Profit | 417.46M |
| Operating Income | -2.97M |
| Pretax Income | -3.26M |
| Net Income | -4.59M |
| EBITDA | 17.75M |
| EBIT | -2.97M |
| Loss Per Share | -$0.10 |
Full Income StatementBalance Sheet
The company has $146.17 million in cash and $74.91 million in debt, with a net cash position of $71.25 million or $1.41 per share.
| Cash & Cash Equivalents | 146.17M |
| Total Debt | 74.91M |
| Net Cash | 71.25M |
| Net Cash Per Share | $1.41 |
| Equity (Book Value) | 491.69M |
| Book Value Per Share | 9.71 |
| Working Capital | 240.50M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $64.36 million and capital expenditures -$10.72 million, giving a free cash flow of $53.64 million.
| Operating Cash Flow | 64.36M |
| Capital Expenditures | -10.72M |
| Depreciation & Amortization | 20.72M |
| Net Borrowing | 4.14M |
| Free Cash Flow | 53.64M |
| FCF Per Share | $1.06 |
Full Cash Flow StatementMargins
Gross margin is 75.61%, with operating and profit margins of -0.54% and -0.83%.
| Gross Margin | 75.61% |
| Operating Margin | -0.54% |
| Pretax Margin | -0.59% |
| Profit Margin | -0.83% |
| EBITDA Margin | 3.22% |
| EBIT Margin | -0.54% |
| FCF Margin | 9.72% |
Dividends & Yields
AtriCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.81% |
| Shareholder Yield | -1.81% |
| Earnings Yield | -0.35% |
| FCF Yield | 4.03% |
Analyst Forecast
The average price target for AtriCure is $51.50, which is 95.97% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $51.50 |
| Price Target Difference | 95.97% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 13.48% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AtriCure has an Altman Z-Score of 7.13 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.13 |
| Piotroski F-Score | 6 |
